Please select the option that best describes you:
Topics:
Hematologic Malignancies • Pediatric Hematology/Oncology • Internal Medicine • ALL • Hematology
With the data from AALL1731, how is blinatumomab being implemented for SR and HR leukemia patients not previously planned/randomized to receive blinatumomab? If in maintenance, is there is certain point at which it is incorporated, or a certain maintenance cycle which it is no longer offered after? Is blinatumomab being offered to SR-Fav patients?
Interested to know how this practice may vary at particular centers